Hepatic Arterial Infusion for Biliary Tract Carcinoma: Single-center Experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F13%3A33145193" target="_blank" >RIV/61989592:15110/13:33145193 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/13:10195440 RIV/00179906:_____/13:10195440

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Hepatic Arterial Infusion for Biliary Tract Carcinoma: Single-center Experience

Popis výsledku v původním jazyce

Aim: The aim of the present study was to evaluate a single-center experience in hepatic arterial infusion (HAI) of patients with biliary tract carcinomas. Patients and Methods: A retrospective analysis of 60 patients treated between 1997 and 2011 was performed. Results: Most patients were treated with HAI of a combination of 5-fluorouracil, folinic acid and cisplatin. The response was not evaluable in most patients, predominantly because of prior surgical procedures. The median survival of all patientswas 15.1 months (5-year survival=13%). The survival was significantly better in patients treated with radical surgery (median=50.1 months, 5-year survival=45%) or palliative surgery (median=22.5 months, 5-year survival=13%) compared to no surgery (median=7.6 months, 5-year survival=3%). Conclusion: The current data demonstrate the efficacy of HAI in patients with biliary tract carcinoma. HAI is a therapeutic method to be considered in patients with inoperable biliary tract carcinoma and

Název v anglickém jazyce

Hepatic Arterial Infusion for Biliary Tract Carcinoma: Single-center Experience

Popis výsledku anglicky

Aim: The aim of the present study was to evaluate a single-center experience in hepatic arterial infusion (HAI) of patients with biliary tract carcinomas. Patients and Methods: A retrospective analysis of 60 patients treated between 1997 and 2011 was performed. Results: Most patients were treated with HAI of a combination of 5-fluorouracil, folinic acid and cisplatin. The response was not evaluable in most patients, predominantly because of prior surgical procedures. The median survival of all patientswas 15.1 months (5-year survival=13%). The survival was significantly better in patients treated with radical surgery (median=50.1 months, 5-year survival=45%) or palliative surgery (median=22.5 months, 5-year survival=13%) compared to no surgery (median=7.6 months, 5-year survival=3%). Conclusion: The current data demonstrate the efficacy of HAI in patients with biliary tract carcinoma. HAI is a therapeutic method to be considered in patients with inoperable biliary tract carcinoma and

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED0030%2F01%2F01" target="_blank" >ED0030/01/01: Biomedicína pro regionální rozvoj a lidské zdroje</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

7

Strana od-do

1201-1207

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—